ELGA Biotech

denunequaledBiotechnology

Dec 1, 2012 (4 years and 6 months ago)

258 views

ELGA Biotech
Innovations in Pharma/Biotech:
Opportunities in Indo-German Co-operation
Amal K. Mukhopadhyay
Amal K. Mukhopadhyay
E
Berlin, June 19, 2006
Berlin, June 19, 2006
GELGA Biotech
Liberalisation Innovation Growth
 Liberalisation and globalisation have
 Liberalisation and globalisation have
produced a pressure on Indian
produced a pressure on Indian
p ph ha ar rm ma ac ce eu ut tiic ca all a an nd d b biio ot te ec ch hn no ollo og gy y iin nd du us st tr ry y
to innovate.
to innovate.
 Pressure to innovate is an important factor
 Pressure to innovate is an important factor
leading to a strong growth in these two
leading to a strong growth in these two
industry branches.
industry branches.
E
GELGA Biotech
New IPR regime in compliance with WTO
 Shift from Process patent to Product patent
 Shift from Process patent to Product patent
regime - will protect all New entrants / entities
regime - will protect all New entrants / entities
from 2005
from 2005
 New patent regulations is causing a major
 New patent regulations is causing a major
structural shift with the entry of foreign players
structural shift with the entry of foreign players
E
GELGA Biotech
Foreign Direct Investment
 Foreign Direct Investment (100 %) has
Foreign Direct Investment (100 %) has
been allowed without prior Govt. approval
been allowed without prior Govt. approval
in most of the cases.
in most of the cases.
 Prior Govt. approval required in some
 Prior Govt. approval required in some
cases involving compulsory licensing
cases involving compulsory licensing
(due to locational policy and a few items
(due to locational policy and a few items
r re es se er rv ve ed d f fo or r s sm ma allll s sc ca alle e s se ec ct to or r) )
E
GELGA Biotech
India: an attractive destination for
Healthcare Companies
- IPR protection
- IPR protection
- Easy norms of FDI
- Easy norms of FDI
coupled with
coupled with
- strong legal system,
- strong legal system,
- - q qu ua alliif fiie ed d a an nd d s sk kiilllle ed d m ma an np po ow we er r,,
- strength in IT and chemistry,
- strength in IT and chemistry,
- a growing middle class and
- a growing middle class and
- increasing number of medical
- increasing number of medical
tourists who can afford expensive health care
tourists who can afford expensive health care
- highly organised clinical research sector
- highly organised clinical research sector
E
GELGA Biotech
German Pharma and Healthcare
companies present in India - I
 Aventis Pharma
Aventis Pharma
 Bayer Diagnostics India Ltd
Bayer Diagnostics India Ltd
 Braun Medical Systems Pvt. Ltd
Braun Medical Systems Pvt. Ltd
 Biersdorf India Ltd Foreign Direct Investment
Biersdorf India Ltd Foreign Direct Investment
 Biomed Hitech Industries Ltd
Biomed Hitech Industries Ltd
 Centres for Medical Innovation (CMI) India Ltd
Centres for Medical Innovation (CMI) India Ltd
 Dornier India Medical Systems Pvt. Ltd
Dornier India Medical Systems Pvt. Ltd
 Dr. Willmar Schwabe India Pvt. Ltd
Dr. Willmar Schwabe India Pvt. Ltd
 Fresenius Kabi India Ltd
Fresenius Kabi India Ltd
 German Remedies Ltd
German Remedies Ltd
 Gland Pharma Ltd
Gland Pharma Ltd
 Hoechst Marian Russell
Hoechst Marian Russell
E
GELGA Biotech
German Pharma and Healthcare
companies present in India - II
 Karl Storz Endoscopy India Pvt. Ltd
 Karl Storz Endoscopy India Pvt. Ltd
 Kendro Lab Products India Ltd
 Kendro Lab Products India Ltd
 KOB Medical Textiles Ltd
 KOB Medical Textiles Ltd
 Madaus Pharmaceuticals (India) Ltd
 Madaus Pharmaceuticals (India) Ltd
 E.Merck
 E.Merck
 Ormed Medical Technology Ltd
 Ormed Medical Technology Ltd
 Otto Bock Healthcare India Pvt. Ltd
 Otto Bock Healthcare India Pvt. Ltd
 Ratiopharm India Pvt. Ltd
 Ratiopharm India Pvt. Ltd
 Schutz Dishman Biotech Ltd
 Schutz Dishman Biotech Ltd
 Toshvin Industries Ltd
 Toshvin Industries Ltd
 Usha Drager Ltd
 Usha Drager Ltd
 Zydus Altana
 Zydus Altana
E
GELGA Biotech
Some of the Foreign Players in India
E
GELGA Biotech
Some of the Top Pharma Cos in India
E
GELGA Biotech
E
Nature, 28th July, 2005
Nature, 28th July, 2005
GELGA Biotech
E
N Na at tu ur re e,, 2 28 8t th h J Ju ully y,, 2 20 00 05 5
GELGA Biotech
Global ambition of Indian Pharmaceutical
Companies
 In this year alone, Ranbaxy announced
 In this year alone, Ranbaxy announced
three acqusitions, Allen S.p.A, a division of
three acqusitions, Allen S.p.A, a division of
Glaxo Smith Kline in Italy, Ethimed in
Glaxo Smith Kline in Italy, Ethimed in
Belgium and Therapia ($ 324 Million) in
Belgium and Therapia ($ 324 Million) in
Romania.
Romania.
 Dr. Reddy’s Lab announced the acquisition
 Dr. Reddy’s Lab announced the acquisition
of Betapharm, Germany at a price of US$
of Betapharm, Germany at a price of US$
581.
581.
 Lupin Laboratories, India buys Daffra
 Lupin Laboratories, India buys Daffra
Pharma in Belgium for an undisclosed sum.
Pharma in Belgium for an undisclosed sum.
E
GELGA Biotech
Indian pharmaceutical industry is expected to
Indian pharmaceutical industry is expected to
register a growth of 11% p.A. enhancing its size to
register a growth of 11% p.A. enhancing its size to
US$ 14 bn by 2007-08, as against US$11 bn in
US$ 14 bn by 2007-08, as against US$11 bn in
2004-05, according to the findings of a study
2004-05, according to the findings of a study
undertaken by ASSOCHAM.
undertaken by ASSOCHAM.
The study says the Indian pharmaceutical exports
The study says the Indian pharmaceutical exports
have tremendous potential to grow at around 18%
have tremendous potential to grow at around 18%
by 2007-08, and take its total export volume to
by 2007-08, and take its total export volume to
about US$ 7 bn as against US$ 4.5 bn in 2004-05.
about US$ 7 bn as against US$ 4.5 bn in 2004-05.
E
GELGA Biotech
Growth in Indian pharmaceutical industry will be
Growth in Indian pharmaceutical industry will be
driven not only by acquisition but also by in-licensing
driven not only by acquisition but also by in-licensing
deals and R & D co-operation.
deals and R & D co-operation.
In health care business, particularly in R&D, the word
In health care business, particularly in R&D, the word
“outsourcing” is being replaced by “partnering” to
“outsourcing” is being replaced by “partnering” to
strengthen the capacity to innovate.
strengthen the capacity to innovate.
E
GELGA Biotech
Glenmark Pharmaceuticals Inc (GPI), has signed a
$27 million royalty deal with international healthcare
investment fund Paul Capital Partners' Royalty Fund
to finance the development of 16 dermatological
products by GPI for the US market.
Lupin in-licenses ItalFarmaco’s cardiovascular
critical care product — enoxaparin sodium. It will be
It will be
manufactured in Milan and Lupin will market it in
manufactured in Milan and Lupin will market it in
India as Lupinox.
India as Lupinox.
Elder Pharmaceuticals has entered into an in-
Elder Pharmaceuticals has entered into an in-
licensing tie-up with Sterisol AB of Sweden to
licensing tie-up with Sterisol AB of Sweden to
develop, manufacture and market medical enviro-
develop, manufacture and market medical enviro-
security products in India.
security products in India.
E
GELGA Biotech
Pharmaceutical industry vs. Biotechnology
Pharma companies are under tremendous
Pharma companies are under tremendous
pressure to reduce prices as competition from
pressure to reduce prices as competition from
Generics increases and regulatory bodies try to
Generics increases and regulatory bodies try to
put a lid on pricing.
put a lid on pricing.
To increase the margin under difficult circumstances
To increase the margin under difficult circumstances
pharma companies look for ways and means to
pharma companies look for ways and means to
reduce the cost of drug discovery process on one
reduce the cost of drug discovery process on one
hand and time taken on the other hand.
hand and time taken on the other hand.
E
GELGA Biotech
Indian Biotechnology Industry
 Turnover reached US $ 1 billion 2005
 Turnover reached US $ 1 billion 2005
 This is only 1% of the world market
 This is only 1% of the world market
 A growth rate of 30% annualised is
 A growth rate of 30% annualised is
expected to increase the total revenue to
expected to increase the total revenue to
US$5.0 billion in 2010.
US$5.0 billion in 2010.
E
GELGA Biotech
Fast growing Indian biotech companies
C Co om mp pa an ny y R Re ev ve en nu ue e 0 03 3- -0 04 4 R Re ev ve en nu ue e 0 04 4- -0 05 5 G Gr ro ow wt th h ( (% %) )
( (U US S$ $ M Miillll..) ) ( (U US S$ $ M Miillll..) )
B Biio oc co on n 1 11 15 5 1 14 48 8 2 29 9
S Se er ru um m IIn ns st t.. 1 12 26 6 1 13 30 0 3 3
P Pa an na ac ce ea a 3 34 4 5 50 0 4 46 6
Bharat Serum 18 19 2
Bharat Serum 18 19 2
IIn nd d IIm mm mu un no o 1 13 3 1 17 7 2 28 8
S Sh ha an nt th ha a B Biio ot te ec c 9 9 1 16 6 7 75 5
Wockhardt 9 15 68
Wockhardt 9 15 68
B Bh ha ar ra at t IIm mm mu un no oll.. 5 5 1 12 2 1 14 47 7
Bharat Biotech 8 9 14
Bharat Biotech 8 9 14
Adv. Biochemicals 7 9 31
Adv. Biochemicals 7 9 31
E
GELGA Biotech
“India is positioned to grow into a major
R&D center for biotechnology companies”
G Steven Burrill is CEO of Burrill & Company, a life sciences
merchant bank engaged in three core activities - venture capital
investment, strategic partnering and strategic advisory services.
Pharmabiz.com, June 2004.
E
GELGA Biotech
Amal K. Mukhopadhyay
Amal K. Mukhopadhyay
a am m@ @e ellg ga ab biio otte ec ch h..c co om m
http://www.elgabiotech.com
http://www.elgabiotech.com
E
G